Compare Bill.com Holdings Inc (BILL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Incyte Corporation — how do they compare? Bill.com Holdings Inc trades at $48.78 (market cap $4.93B), while Incyte Corporation trades at $120.8 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 5× Bill.com Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BILL | INCY | |
|---|---|---|
Market Cap | $4.93B | $24.54B |
Sector | Technology | Health |
52-Week High | $56.32 | $129.93 |
52-Week Low | $31.96 | $81.61 |
Enterprise Value | $4.64B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.63, down 1.28% on the day, with a bullish technical signal from moving averages and positive earnings beats in recent quarters. Revenue growth is strong, reaching $1.46B in 2025, but profitability remains thin with a net income margin of just 0.01%. The company is focusing on AI-driven automation and operational efficiency, including a recent 30% workforce reduction and new executive appointments to spur growth.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56%) and a price target implying modest upside. Key risks include intense fintech competition and the challenge of translating high revenue into sustained profitability. Cash flow trends show improvement, but investors should monitor execution on margin expansion and competitive positioning.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
